U.S. FOOD AND DRUG ADMINISTRATION: FDA approves new oral treatment for multiple sclerosis
The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease